Boehringer Ingelheim sales and marketing update

Boehringer launched Striverdi Respimat olodaterol in the U.S. to treat airflow limitations in patients with chronic obstructive pulmonary disease (COPD). The wholesale acquisition cost (WAC) of the 5...